JP MORGAN/PUT/MODERNA/110/0.1/20.06.25 | Market Closed - Börse Stuttgart 20:50:58 28/06/2024 BST | ||
| 1.66 EUR | +3.75% |
|
| Current month | +39.50% | ||
| 1 month | +53.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 1.66 | +3.75% |
| 27/06/24 | 1.6 | +1.91% |
| 26/06/24 | 1.57 | +27.64% |
| 25/06/24 | 1.23 | -0.81% |
| 24/06/24 | 1.24 | -6.06% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JK5ZN3 |
| ISIN | DE000JK5ZN38 |
| Date issued | 13/03/2024 |
| Strike | 110 $ |
| Maturity | 20/06/2025 (355 Days) |
| Parity | 10 : 1 |
| Emission price | 2.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.54 € |
|---|---|
| Lowest since issue | 0.89 € |
| Spread | 0.09 € |
| Spread % | 5.14% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
